3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
4
Lung Neoplasms
4
Glioma
4
Neoplasm Metastasis
3
Glioblastoma
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Gliosarcoma
2
Esophageal Neoplasms
2
Carcinoma, Medullary
2
Breast Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Interventions
Everolimus
2
veliparib
1
vatalanib
1
vandetanib
1
temsirolimus
1
spartalizumab
1
pentetreotide
1
gallium Ga 68 dotatate
1
fluorodopa F 18
1
fludarabine phosphate
1
Vinorelbine
1
Temozolomide
1
Specimen Handling
1
Sirolimus
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Interleukin-13
1
High-Energy Shock Waves
1
Fluorodeoxyglucose F18
1
Floxuridine
1
Cyclophosphamide
1
Capecitabine
1
Biopsy
1
6-fluorodopamine
1
3-Iodobenzylguanidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Pheochromocytoma
×
vandetanib
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn